For the year ending 2025-12-31, CNSP has $8,623,466 in assets. $4,100,910 in debts. $7,201,014 in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 7,201,014 | |||
| Deferred offering costs | 45,486 | |||
| Subscription receivable | 0 | |||
| Prepaid expenses and other current assets | 856,301 | |||
| Total current assets | 8,102,801 | |||
| Prepaid expenses, net of current portion | 502,962 | |||
| Property and equipment, net | 17,703 | |||
| Total noncurrent assets | 520,665 | |||
| Total assets | 8,623,466 | |||
| Accounts payable and accrued expenses | 3,772,339 | |||
| Notes payable | 328,571 | |||
| Total current liabilities | 4,100,910 | |||
| Total liabilities | 4,100,910 | |||
| Common stock, 0.001 par value, 300,000,000 shares authorized and 632,516 and 117,796 shares issued and outstanding, respectively | 633 | |||
| Additional paid-in capital | 104,797,191 | |||
| Accumulated deficit | -100,275,268 | |||
| Total stockholders' equity (deficit) | 4,522,556 | |||
| Total liabilities and stockholders' equity (deficit) | 8,623,466 | |||
CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc. (CNSP)